Sarah A Holstein

List of Publications by Year
in descending order

122 papers	3,501 citations	236612 25 h-index	149479 56 g-index
125 all docs	125 docs citations	125 times ranked	3782 citing authors

#	Article	IF	Citations
1	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 3279-3289.	0.8	535
2	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood, 2020, 136, 936-945.	0.6	436
3	Isoprenoids: Remarkable diversity of form and function. Lipids, 2004, 39, 293-309.	0.7	206
4	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs, 2017, 77, 505-520.	4.9	150
5	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 11-20.	2.3	142
6	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	5.1	136
7	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	2.2	132
8	CAR Tâ€Cell Therapy in Hematologic Malignancies: A Voyage in Progress. Clinical Pharmacology and Therapeutics, 2020, 107, 112-122.	2.3	111
9	Consequences of Mevalonate Depletion. Journal of Biological Chemistry, 2002, 277, 10678-10682.	1.6	84
10	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	2.8	75
11	Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Analytical Biochemistry, 2005, 336, 51-59.	1.1	72
12	Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology, 2006, 57, 155-164.	1.1	69
13	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	3.3	69
14	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	3.4	67
15	Isoprenoids Influence Expression of Ras and Ras-Related Proteins. Biochemistry, 2002, 41, 13698-13704.	1.2	61
16	Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leukemia Research, 2001, 25, 651-660.	0.4	58
17	Update on the role of lenalidomide in patients with multiple myeloma. Therapeutic Advances in Hematology, 2018, 9, 175-190.	1.1	42
18	Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Research, 2011, 35, 551-559.	0.4	41

#	Article	IF	Citations
19	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Advances, 2017, 1, 1056-1066.	2.5	40
20	Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase. ACS Medicinal Chemistry Letters, 2015, 6, 1195-1198.	1.3	38
21	Monoterpene regulation of Ras and Ras-related protein expression. Journal of Lipid Research, 2003, 44, 1209-1215.	2.0	34
22	Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leukemia Research, 2005, 29, 527-533.	0.4	34
23	Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leukemia Research, 2009, 33, 344-347.	0.4	33
24	Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorganic and Medicinal Chemistry, 2014, 22, 2791-2798.	1.4	33
25	Î±-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 376-385.	1.4	27
26	Is there a future for prenyltransferase inhibitors in cancer therapy?. Current Opinion in Pharmacology, 2012, 12, 704-709.	1.7	26
27	Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors. Molecules, 2017, 22, 886.	1.7	26
28	Triazole-based inhibitors of geranylgeranyltransferase II. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 764-766.	1.0	25
29	Isoprenoid Pyrophosphate Analogues Regulate Expression of Ras-Related Proteins. Biochemistry, 2003, 42, 4384-4391.	1.2	23
30	Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, 793-798.	2.0	23
31	Role of stem cell transplant and maintenance therapy in plasma cell disorders. Hematology American Society of Hematology Education Program, 2016, 2016, 504-511.	0.9	22
32	Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget, 2015, 6, 41535-41549.	0.8	22
33	Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorganic and Medicinal Chemistry, 2017, 25, 2437-2444.	1.4	21
34	Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Oncogene, 2019, 38, 5308-5320.	2.6	21
35	Stereoselective Synthesis of Homoneryl and Homogeranyl Triazole Bisphosphonates. Journal of Organic Chemistry, 2016, 81, 9438-9442.	1.7	20
36	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. Blood, 2021, 138, 79-79.	0.6	20

#	Article	IF	Citations
37	Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Research, 2010, 34, 344-351.	0.4	19
38	Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase. Molecular Pharmacology, 2017, 91, 229-236.	1.0	19
39	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
40	A patent review of bisphosphonates in treating bone disease. Expert Opinion on Therapeutic Patents, 2019, 29, 315-325.	2.4	19
41	Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS. Molecules, 2018, 23, 3275.	1.7	18
42	Pleiotropic Effects of a Schweinfurthin on Isoprenoid Homeostasis. Lipids, 2011, 46, 907-921.	0.7	17
43	Novel Î±-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis. Pharmacological Research, 2016, 113, 438-448.	3.1	17
44	Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. Oncotarget, 2017, 8, 76085-76098.	0.8	17
45	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
46	Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor. Investigational New Drugs, 2018, 36, 810-818.	1.2	15
47	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. Current Hematologic Malignancy Reports, 2019, 14, 31-38.	1.2	15
48	A new motif for inhibitors of geranylgeranyl diphosphate synthase. Bioorganic and Medicinal Chemistry, 2016, 24, 3734-3741.	1.4	14
49	In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 327-338.	1.3	14
50	Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e129-e131.	0.2	13
51	Quantitative Determination of Geranyl Diphosphate Levels in Cultured Human Cells. Lipids, 2009, 44, 1055-1062.	0.7	12
52	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
53	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplantation, 2019, 54, 497-507.	1.3	11
54	N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2331-2334.	1.0	10

#	Article	IF	Citations
55	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opinion on Pharmacotherapy, 2017, 18, 1975-1985.	0.9	10
56	Isoprenoid Amide Bisphosphonates As a Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors. Blood, 2018, 132, 4679-4679.	0.6	10
57	Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study. Blood, 2021, 138, 898-898.	0.6	10
58	Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. Journal of Geriatric Oncology, 2022, 13, 871-874.	0.5	9
59	Present and Future of Immunotherapy in the Management of Multiple Myeloma. Journal of Oncology Practice, 2018, 14, 403-410.	2.5	8
60	Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. Journal of Clinical Oncology, 2018, 36, 2101-2104.	0.8	8
61	Electrophysiological Measure of Impaired Information Processing in Drivers with Hematological Malignancy. Transportation Research Record, 2018, 2672, 64-73.	1.0	8
62	Ï‰-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126633.	1.0	8
63	Future Directions in Maintenance Therapy in Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 2261.	1.0	8
64	Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.. Journal of Clinical Oncology, 2022, 40, e20021-e20021.	0.8	8
65	Stereocontrolled regeneration of olefins from epoxides. Tetrahedron Letters, 2016, 57, 1335-1337.	0.7	7
66	Modeling the Effects of Multiple Myeloma on Kidney Function. Scientific Reports, 2019, 9, 1726.	1.6	7
67	In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway. Pharmacological Research, 2021, 167, 105528.	3.1	7
68	Impact of Î±-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2021, 44, 116307.	1.4	7
69	Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults with Acute Myeloid Leukemia (AML). Blood, 2019, 134, 120-120.	0.6	7
70	Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 594-602.	1.2	6
71	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy, 2019, 19, 889-898.	1.1	6
72	Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron. Leukemia Research, 2019, 77, 17-27.	0.4	6

#	Article	IF	Citations
73	Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e239-e258.	0.2	6
74	Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs, 2021, 81, 825-840.	4.9	6
75	Novel benzimidazole phosphonates as potential inhibitors of protein prenylation. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126757.	1.0	5
76	Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?. Current Hematologic Malignancy Reports, 2019, 14, 39-46.	1.2	5
77	Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study. Journal of the Neurological Sciences, 2020, 410, 116644.	0.3	5
78	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
79	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1414-1424.	2.0	5
80	Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550). Blood, 2019, 134, 4451-4451.	0.6	5
81	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 2022, 12, 63.	2.8	5
82	Multiple Myeloma. Hematology/Oncology Clinics of North America, 2014, 28, 1113-1129.	0.9	4
83	Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LCâ€“MS/MS: Derivatization and application. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 22-28.	1.4	4
84	Amides as bioisosteres of triazole-based geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115604.	1.4	4
85	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	4
86	Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma. Experimental Hematology and Oncology, 2022, 11, 5.	2.0	4
87	The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patientâ€Focused Precision Therapeutics. Clinical Pharmacology and Therapeutics, 2020, 108, 399-404.	2.3	3
88	Melflufen: A Next-Generation Nitrogen Mustard. Journal of Clinical Oncology, 2021, 39, 836-839.	0.8	3
89	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	0.6	3
90	Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin. Blood, 2021, 138, 2723-2723.	0.6	3

#	Article	IF	Citations
91	BIA 10â€2474: Some Lessons are Clear but Important Questions Remain Unanswered. Clinical Pharmacology and Therapeutics, 2022, 111, 343-345.	2.3	3
92	The Peptideâ€“Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. HemaSphere, 2022, 6, e687.	1.2	3
93	A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022. Expert Review of Anticancer Therapy, 2022, , 1-13.	1.1	3
94	Review: Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention. Current Cancer Drug Targets, 2022, 22, .	0.8	3
95	Commentary on â€œIs posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myelomaâ€• by Giovanni Barosi and Robert Peter Gale. Leukemia, 2019, 33, 565-566.	3.3	2
96	Oncology Treatment in the Era of COVIDâ€19: We Cannot Afford to Hit the Pause Button. Clinical Pharmacology and Therapeutics, 2020, 108, 422-424.	2.3	2
97	In Vitro and inVivo Activity of Melflufen in Amyloidosis. Blood, 2019, 134, 3100-3100.	0.6	2
98	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. Expert Review of Clinical Pharmacology, 2022, , 1-13.	1.3	2
99	Quantitative Clinical Pharmacology of CAR Tâ€Cell Therapy. Clinical Pharmacology and Therapeutics, 2022, 112, 11-15.	2.3	2
100	Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research. Neuro-Ophthalmology, 2020, 44, 139-147.	0.4	1
101	Treatment Considerations for Transplant-Ineligible Multiple Myeloma. Oncology, 2021, 35, 170-182.	0.4	1
102	Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2021, 39, 7021-7021.	0.8	1
103	In Vivo Evaluation of Novel Geranylgeranyl Diphosphate Synthase Inhibitors. Blood, 2018, 132, 215-215.	0.6	1
104	A Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors: Structure-Activity Relationships of Homoisoprenoid Triazoles in Myeloma Cells. Blood, 2014, 124, 2156-2156.	0.6	1
105	Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. Blood, 2016, 128, 2274-2274.	0.6	1
106	Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).. Journal of Clinical Oncology, 2018, 36, 8050-8050.	0.8	1
107	Allogeneic Stem Cell Transplantation for Multiple Myeloma: A 34-Year Experience. Blood, 2018, 132, 5780-5780.	0.6	1
108	Continued role for ASCT in multiple myeloma. Lancet Oncology, The, 2015, 16, 1571-1573.	5.1	0

#	Article	IF	Citations
109	Autologous Stem-Cell Transplantation for Myeloma: Here to Stay?. JCO Oncology Practice, 2020, 16, 67-68.	1.4	0
110	Visual dysfunction in a mouse model of chemotherapy-related neurotoxicity.. Journal of Clinical Oncology, 2021, 39, e24059-e24059.	0.8	0
111	Biochemical Basis for Interactions Between Thalidomide and Inhibitors of the Isoprenoid Biosynthetic Pathway in Multiple Myeloma Cells. Blood, 2008, 112, 2635-2635.	0.6	0
112	Interaction Between Heat Shock Protein Inhibitors and Isoprenoid Biosynthetic Pathway Inhibitors In Multiple Myeloma Cells. Blood, 2010, 116, 2895-2895.	0.6	0
113	Evaluation of Autophagy Modulators and Isoprenoid Biosynthetic Pathway Inhibitors in Multiple Myeloma Cells. Blood, 2011, 118, 2488-2488.	0.6	0
114	Targeting Rab Geranylgeranylation Disrupts Myeloma-Stromal Cell Interactions. Blood, 2012, 120, 1354-1354.	0.6	0
115	Synthesis and Structure-Function Relationship Of Novel Triazole Phosphonates As Inhibitors Of Rab Geranylgeranyl Transferase. Blood, 2013, 122, 4223-4223.	0.6	0
116	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. Blood, 2016, 128, 3454-3454.	0.6	0
117	Effects of Isoprenoid Biosynthetic Pathway Inhibition on Glucose Uptake in Myeloma Cells. Blood, 2016, 128, 3300-3300.	0.6	0
118	Synergistic Inhibition of Geranylgeranyl Diphosphate Synthase By a Mixture of Olefin Stereoisomers. Blood, 2016, 128, 2320-2320.	0.6	0
119	Effects of a temporal break between mobilization and conditioning on complications and hospitalization charges in multiple myeloma patients undergoing autologous stem cell transplant (ASCT).. Journal of Clinical Oncology, 2018, 36, e20002-e20002.	0.8	0
120	Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma. Blood, 2019, 134, 4417-4417.	0.6	0
121	Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2155-2155.	0.6	0
122	The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience. Blood, 2019, 134, 2028-2028.	0.6	0